Cenexi annual summer shutdown impact
Cenexi's annual summer shutdown (4 weeks in France, 3 in Belgium) will continue to cause revenue loss and negative EBITDA in Q2 each year.
GLAND / Q2-FY24 / risks
Keep the risk register visible.
Gland Pharma · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
medium
Enoxaparin pricing and volume pressure in ROW markets
ROW revenue declined 9% QoQ due to lower Enoxaparin volumes and pricing pressure from competition, with management noting very low margins.
Cenexi margin improvement timeline uncertain
Management declined to provide a timeline for Cenexi reaching 13-15% EBITDA margins, citing early stage of integration.
Potential dilution from milestone income volatility
Milestone income (5% of ex-Cenexi revenue in Q2) can fluctuate between 5-10%, impacting quarterly comparability.